Evidence map›Paper›PMID 26473355›Full record

ArticlePloS one2015

The Genotype of the Donor for the (GT)n Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Does Not Affect the GVL Effect after Myeloablative HLA-Identical Allogeneic Stem Cell Transplantation.

Víctor Noriega, Carolina Martínez-Laperche, Elena Buces, Marjorie Pion, Noemí Sánchez-Hernández, Beatriz Martín-Antonio, Vicent Guillem, Anna Bosch-Vizcaya, Leyre Bento, Milagros González-Rivera and 20 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Solution Structure of Poly(UG) RNA.Journal of molecular biology · 2023
    Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 15 institutions in 1 country.

Víctor NoriegaDepartment of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
Carolina Martínez-LapercheDepartment of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
Elena BucesDepartment of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
Marjorie PionInstituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain; Department of Inmunology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Noemí Sánchez-HernándezDepartment of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Beatriz Martín-AntonioDepartment of Hematology, Hospital Clinic, University of Barcelona, IDIBAPS, Instituto de Investigación Josep Carreras (IJC), Barcelona, Spain.
Vicent GuillemDepartment of Hematology and Medical Oncology, Hospital Clínico Universitario de Valencia, Universitat de Valencia, Instituto de Investigación Sanitaria INCLIVA, Valencia, Spain.
Anna Bosch-VizcayaDepartment of Hematology, ICO Girona, Hospital Josep Trueta, IDIBGI Foundation, Girona, Spain.
Leyre BentoDepartment of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Milagros González-RiveraInstituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain; DNA Sequencing Core Facility, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Pascual BalsalobreDepartment of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
Mi KwonDepartment of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
David SerranoDepartment of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
Jorge GayosoDepartment of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
Rafael de la CámaraDepartment of Hematology, Hospital La Princesa, Madrid, Spain.
Salut BrunetDepartment of Clinical Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Rafael Rojas-ContrerasDepartment of Hematology, Hospital Reina Sofia, Cordoba, Spain.
José B NietoDepartment of Hematology, Hospital Morales Meseguer, Murcia, Spain.
Carmen MartínezDepartment of Hematology, Hospital Clínic, Barcelona, Spain.
Marcos GónzalezDepartment of Hematology, University Hospital of Salamanca, Salamanca, Spain.
Ildefonso EspigadoDepartment of Hematology and Hemotherapy, Hospital Universitario Virgen del Rocío, Seville, Spain.
Juan C VallejoDepartment of Hematology, Hospital Universitario Central de Asturias, Oviedo, Spain.
Antonia SampolDepartment of Hematology, Hospital Universitario Son Espases, Palma de Mallorca, Islas Baleares, Spain.
Antonio Jiménez-VelascoDepartment of Hematology, Hospital Regional Universitario de Málaga, Málaga, Spain.
Alvaro Urbano-IspizuaDepartment of Hematology, Hospital Clinic, University of Barcelona, IDIBAPS, Instituto de Investigación Josep Carreras (IJC), Barcelona, Spain.
Carlos SolanoDepartment of Hematology and Medical Oncology, Hospital Clínico Universitario de Valencia, Universitat de Valencia, Instituto de Investigación Sanitaria INCLIVA, Valencia, Spain.
David GallardoDepartment of Hematology, ICO Girona, Hospital Josep Trueta, IDIBGI Foundation, Girona, Spain.
José L Díez-MartínDepartment of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
Ismael BuñoDepartment of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH)
Hospital General Universitario Gregorio Marañón · ESHospital Clínico Universitario de Valencia · ESInstitut d'Investigació Biomèdica de Girona · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESHospital Clínic de Barcelona · ESHospital de Sant Pau · ESHospital General Universitario Morales Meseguer · ESHospital Regional Universitario de Málaga · ESHospital Universitario Central de Asturias · ESHospital Universitario de La Princesa · ESHospital Universitario Reina Sofía · ESHospital Universitario Son Espases · ESHospital Universitario Virgen del Rocío · ESUniversidad de Salamanca · ESUniversitat de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The FOXP3 gene encodes for a protein (Foxp3) involved in the development and functional activity of regulatory T cells (CD4+/CD25+/Foxp3+), which exert regulatory and suppressive roles over the immune system. After allogeneic stem cell transplantation, regulatory T cells are known to mitigate graft versus host disease while probably maintaining a graft versus leukemia effect. Short alleles (≤(GT)15) for the (GT)n polymorphism in the promoter/enhancer of FOXP3 are associated with a higher expression of FOXP3, and hypothetically with an increase of regulatory T cell activity. This polymorphism has been related to the development of auto- or alloimmune conditions including type 1 diabetes or graft rejection in renal transplant recipients. However, its impact in the allo-transplant setting has not been analyzed. In the present study, which includes 252 myeloablative HLA-identical allo-transplants, multivariate analysis revealed a lower incidence of grade III-IV acute graft versus host disease (GVHD) in patients transplanted from donors harboring short alleles (OR = 0.26, CI 0.08-0.82, p = 0.021); without affecting chronic GVHD or graft versus leukemia effect, since cumulative incidence of relapse, event free survival and overall survival rates are similar in both groups of patients.

Indexed as

Graft vs Leukemia EffectPolymorphism, GeneticAdultAgedFemaleForkhead Transcription FactorsGenetic Association StudiesGenotypeGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedPromoter Regions, GeneticSurvival AnalysisTissue DonorsForkhead Transcription FactorsFOXP3 protein, human

Identifiers

PMID26473355
PMCPMC4608671
OpenAlexW2225633802

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.